CNS-5161

CNS-5161 is an NMDA receptor antagonist which was under development for the treatment of neuropathic pain and cancer pain but was never marketed.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

CNS-5161 is an NMDA receptor antagonist which was under development for the treatment of neuropathic pain and cancer pain but was never marketed. It is taken by intravenously or transdermally. CNS-5161 was under development by CeNeS Pharmaceuticals. It reached phase 2 trials prior to the discontinuation of its development.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1376787595 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.